Recs

5

3 Stocks Approaching Greatness

For every stock out there screaming "buy me," others simply give us a nudge and a nod. While all the attention might be focused on their five-star peers, we can sift through Motley Fool CAPS to find four-star stocks giving us the "high sign" they're approaching greatness. 

These opportunities -- including familiar names and beaten-down companies -- rank higher than most of the other 5,400 starred companies, and it pays to investigate their potential. For consideration today I've got this handful of stocks on their way to fame.

  • Amarin (Nasdaq: AMRN  )
  • SUPERVALU (NYSE: SVU  )
  • TD AMERITRADE (Nasdaq: AMTD  )

As the 180,000-member CAPS community has chosen these companies as less obvious sources for tomorrow's great buys, let's see why they might merit your attention.

In the sight of greatness?
Even if management says it doesn't want to get acquired, preferring to remain a stand-alone cardiovascular disease drug developer (a sentiment that actually sent its stock lower), Amarin seems destined to be one of those companies that will get swallowed up anyway.

Its triglyceride-lowering fish oil therapy, AMR101, is ready to submit a new drug application in the fall, and by all appearances the drug should do better than either GlaxoSmithKline's Lovaza or Abbott Labs' (NYSE: ABT  ) Tricor and Trilipix.

Despite Amarin's stock being up more than 540% over the past year, earnings next year are expected to double with long-term growth rates pegged at 65%. Getting the drug on the market seems geared to send the drugmaker higher still.

CAPS member serenas5 agrees, and says that if management remains intransigent to offers that are sure to follow, someone will take it directly to the shareholders:

[Amarin] has a drug that has produced significant results via its 2 completed phase 3 trials. It has opened the eyes of many big pharma companies. I think it will be involved in a hostile takeover prior to the end of the year.

Let us know on the Amarin CAPS page whether it will ascend to even loftier heights as a result of its grand plan.

Food for thought
As if competition from Wal-Mart and Kroger (NYSE: KR  ) wasn't enough, supermarket chain SUPERVALU has been contending with a heavy debt load that's weighing it down. As CAPS member JPAKolypse86 points out, the company's market cap of $2 billion is dwarfed by its billions more in indebtedness. Yet this CAPS member goes on to note that the grocer is slowly paying down the balance and offers a healthy dividend yielding 3.7% currently:

Now the good news. There have been downers saying that these guys won't last another month for almost a year now. Yet they are still here. And they are paying down their debt a little bit at a time, like good accountants do. It will take a while for them to get back into safe territory, but i believe that the worst is behind them.

Challenges remain, of course, before SUPERVALU can realize its full potential. Rising commodity costs are pinching margins for grocers caught between the rock of absorbing some of the increases and the hard place of passing them along. SUPERVALU reported better-than-expected earnings this morning as it was able to cut costs, but it will be tough to determine where else it can trim.

Labor problems could also impede its growth. SUPERVALU, Kroger, and Safeway (NYSE: SWY  ) agreed to a profit-sharing plan in 2003 in the event that unions struck against any of them, but a federal appeals court now says they may have violated antitrust laws.

The CAPS community generally thinks SUPERVALU will be able to overcome these hurdles, as 98% of the All-Stars weighing in believe it will beat the market indexes going forward. Add SUPERVALU to your Foolish watchlist and see if the grocer can make you some green.

Trading up
I ended up having my brokerage accounts at TD AMERITRADE because it bought up discounter Datek many years ago. I had switched over from E*TRADE Financial (Nasdaq: ETFC  ) because I do all my own research and, at the time, E*TRADE's transaction fees were significantly more than the discounters' while the tools available were on par with everyone else.

Now it looks like I might have ended up at AMERITRADE even if I had stayed with E*TRADE, since the latter's biggest shareholder urged it to put itself up for sale and TD AMERITRADE is interested in making a bid. As one of the more robust investment houses, it might be said to have the inside track on a successful offer.

The markets definitely liked the idea of AMERITRADE buying E*TRADE, as shares are 10% higher this week, though Charles Schwab might also be considered a suitor, as could Bank of America.

CAPS member jquigretired saw AMERITRADE as an all-around solid investment even before the acquisition speculation began:

[TD AMERITRADE] is a solid brokerage firm, both online and in their branch offices. They have a large amount of research items for investors to use, and good information for the new investor as well. A decent dividend @.20 per share, overall I see this company moving forward into the next year.

Let us know in the comments section below or on the TD AMERITRADE CAPS page if you think its buying E*TRADE is the right trade.

A great opportunity for you
Investor sentiment suggests these four-star investments seem to be on their way to five-star greatness, but it pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.

Sign up today for the completely free service and let us hear what you have to say about the great and almost-great companies that interest you.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

The Motley Fool owns shares of GlaxoSmithKline, SUPERVALU, Wal-Mart, and Abbott Labs. Motley Fool newsletter services have recommended buying shares of Abbott Labs, GlaxoSmithKline, Charles Schwab, and Wal-Mart. Motley Fool newsletter services have recommended creating a diagonal call position in Wal-Mart. Motley Fool newsletter services have recommended buying calls in SUPERVALU. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his portfolio here. The Motley Fool has a disclosure policy.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 26, 2011, at 7:11 PM, tvjunkie2 wrote:

    Yes, AMTD should buy ETFC. I am long ETFC :-).

  • Report this Comment On July 27, 2011, at 10:36 AM, yazzbro wrote:

    I am sure Motley Fool is on the brink of booting me from their website because of my opinion on Amarin. They are really plugging Amarin big time which I don't entirely disagree with. But, I do disagree on some things. One, I really doubt that Amarin will be involved in any type of Hostile take over scenario. Why? Is Amarin management that arrogant or inept to get into a situation like that? Why wouldn't they just sell? I am sure they are all holding heavy positions of Amarin stock. A buyout would allow all of them to retire quite comfortably. So the hostile take over proposition is a very, very, remote one. Less than 1% chance that happens. My second argument is the stock moving up on earnings. What earnings? There are no earnings. And it wont have any earnings next year, or the year after that or the year after that unless someone partners up with them. That partnership probably wont happen until after the FDA approval which is at least 6 months away at this point. So earnings for most of next year are out. Another thing to think about is that Amarin is going to have plenty of competition with Lovaza and Lipitor going generic next year. Yes, Amarin is marginally better than both of those meds but, the generic meds will be way, way cheaper. Also, a company called Neptune (NEPT) is in phase 2 trials for a Omega 3 Krill Oil that is actually supposed to perform better than the Amarin 101.(That remains to be seen but just throwing that out there.) My last thing is lately, there has been way to much positive press about Amarin and a rumor that was spun last week about Pfizer buying it. Which to me is troublesome. Usually when bolgnia like that is happening someone out there is holding a heavy position and wants to get out of it at what they paid for it. What I do agree with though, is that Amarin still has some upside to it. With the FDA approval the price should jump into the $20's no problem. That might be a good time to exit your positions because, I don't think that buyout everyone is hoping for is coming. I hope I am wrong on that but, a buyout probably would have been in the works by now. Just some fish food for thought. Happy Trading all..

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1525135, ~/Articles/ArticleHandler.aspx, 5/26/2012 10:19:44 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 13 hours ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:00 PM
SVU $4.76 Up +0.10 +2.15%
SUPERVALU INC. CAPS Rating: ***
AMTD $17.24 Up +0.19 +1.11%
TD AMERITRADE Hold… CAPS Rating: *****
AMRN $11.55 Up +0.40 +3.59%
Amarin Corp plc (A… CAPS Rating: ****
KR $22.41 Up +0.26 +1.17%
The Kroger Co. CAPS Rating: ***
SWY $19.22 Up +0.39 +2.07%
Safeway, Inc. CAPS Rating: **
ABT $62.25 Down -0.17 -0.27%
Abbott Laboratorie… CAPS Rating: *****
ETFC $8.68 Down -0.08 -0.91%
E*TRADE Financial… CAPS Rating: ****

Advertisement